How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,491 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. General Principles of Poisoning

General Principles of Poisoning General Principles of Poisoning - Injuries; Poisoning - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge (...) , which are unpredictable and not dose-related, and from intolerance, which is a toxic reaction to a usually nontoxic dose of a substance. Poisoning is commonly due to ingestion but can result from injection, inhalation, or exposure of body surfaces (eg, skin, eye, mucous membranes). Many commonly ingested nonfood substances are generally nontoxic (see Table: ); however, almost any substance can be toxic if ingested in excessive amounts. Table Substances Usually Not Dangerous When Ingested* Adhesives

2013 Merck Manual (19th Edition)

62. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes

-of-rights). Page 3 of 131 1 Recommendations Recommendations 1.1 Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: a dipeptidyl peptidase 4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. 1.2 Ertugliflozin in a dual-therapy regimen in combination with metformin (...) is recommended as an option for treating type 2 diabetes, only if: a sulfonylurea is contraindicated or not tolerated or the person is at significant risk of hypoglycaemia or its consequences. 1.3 If patients and their clinicians consider ertugliflozin to be 1 of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen. 1.4 These recommendations are not intended to affect treatment with ertugliflozin that was started in the NHS before

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

63. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

2 diabetes mellitus 1 Table 3: Dapagliflozin/metformin – probability and extent of added benefit 4 Table 4: Research question of the benefit assessment of dapagliflozin/metformin in type 2 diabetes mellitus 5 Table 5: Study pool of the company – RCT, direct comparison: dapagliflozin/metformin vs. sulfonylurea + metformin 6 Table 6: Characteristics of the DapaZu study included by the company – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 8 Table 7: Characteristics (...) and Efficiency in Health Care (IQWiG) - 1 - 2 Benefit assessment 2.1 Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned IQWiG to assess the benefit of the drug combination dapagliflozin/metformin. The company submitted a first dossier on the drug combination on 15 February 2014 to be evaluated for the early benefit assessment. The company now requested a new benefit assessment for a subindication – i.e

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

64. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

4 Table 4: Research question of the benefit assessment of dapagliflozin in type 2 diabetes mellitus 5 Table 5: Study pool of the company – RCT, direct comparison: dapagliflozin+metformin vs. sulfonylurea + metformin 6 Table 6: Characteristics of the DapaZu study included by the company – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 7 Table 7: Characteristics of the intervention – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 8 (...) ”) submitted a first dossier of the drug to be evaluated on 15 December 2012 for the early benefit assessment. The company now requested a new benefit assessment for a subindication – i.e. an add-on combination therapy with metformin – because of new scientific findings. The assessment was based on a dossier compiled by the pharmaceutical company. The dossier was sent to IQWiG on 21 December 2017. Research question The aim of this report was to assess the added benefit of dapagliflozin for the treatment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

65. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD

Sulfonylureas 38 8.5.3 Thiazolidinediones 38 8.5.4 Dipeptidyl peptidase-4 inhibitors 38 8.5.5 Glucagon-like peptide-1 receptor agonists 38 8.5.6 Sodium-glucose co-transporter 2 inhibitors 38 9 Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death 40 9.1 Atrial fibrillation 40 9.1.1 Diabetes and risk of stroke in atrial fibrillation 40 9.2 Ventricular arrhythmias and sudden cardiac death 40 9.2.1 Ventricular premature beats and paroxysmal ventricular tachycardia 40 9.2.2 (...) -centred care 46 12.1 General aspects 46 13 ‘What to do’ and ‘what not to do’ messages from the Guidelines 48 14 Appendix 51 15 References 52 Recommendations Recommendations for the diagnosis of disorders of glucose metabolism 12 Recommendations for the use of laboratory, electrocardiogram, and imaging testing for cardiovascular risk assessment in asymptomatic patients with diabetes 16 Recommendations for lifestyle modifications for patients with diabetes mellitus and pre-diabetes 18 Recommendations

Full Text available with Trip Pro

2019 European Society of Cardiology

66. Acute Kidney Injury (AKI)

be complementary rather than contradictory, bridging the gap between the predominantly practical approach of Think Kidneys and the evidence-driven methodology of NICE and seeking to harmonise available guidance. The final scope for the present guidelines was confirmed after posting of a preliminary draft on the Renal Association website between 20 th December 2016 and 28 th February 2017. Literature search terms were then defined, as detailed in appendix 1, but, briefly: The generic, AKI literature was first (...) broader, AKI care processes (e.g. documentation of differential diagnoses of newly detected AKI episodes). The first draft of the guideline was posted on the Renal Association website on January 2019. The draft guideline was also circulated amongst key stakeholder organisations, comprising: ? Kidney Care UK ? The National Kidney Federation ? The Think Kidneys programme ? The Intensive Care Society ? The Association of Clinical Biochemists ? The Society of Acute Medicine ? The British Association

2019 Renal Association

67. Heart Disease and Stroke Statistics

–0.92) mortality than those treated at noncertified hospitals, after adjustment for demographic and clinical factors. Hospitals certified between 2009 and 2013 also had lower in-hospital and 30-day mortality than centers certified before 2009. Congenital Cardiovascular Defects and Kawasaki Disease (Chapter 15) Although estimates of birth prevalence/overall prevalence of congenital cardiovascular defects appear relatively stable, a general trend toward improved outcome/survival continues, which has (...) led to an expanding population of adult congenital heart disease patients. Although there remains increased mortality in patients with congenital cardiovascular defects compared with the general population, the standardized mortality ratios after congenital heart disease surgery continue to decrease. In a recent study from the Pediatric Cardiac Care Consortium’s US-based multicenter data registry, which examined 35 998 patients with a median follow-up of 18 years, the overall standardized

Full Text available with Trip Pro

2019 American Heart Association

68. Type 1 diabetes

that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak (...) peptide- 1 (GLP- 1 ) receptor agonists ( ). Guideline Focus and Target Population Since the publication of the 2012 American College of Physicians (ACP) guideline on the comparative effectiveness and safety of oral medications for the treatment of type 2 diabetes , several new studies (...) for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project Journals Library An error occurred retrieving content to display, please try again 2017 9. ) instrument was used to evaluate the guidelines. Guidance Statement 1 : Clinicians should personalize goals for glycemic control in patients with type 2 diabetes on the basis of a discussion of benefits and harms of pharmacotherapy, patients' preferences, patients' general health and life expectancy

2018 Trip Latest and Greatest

69. Sitagliptin

. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study Record Detail Study to Compare Sitagliptin Versus Sulfonylurea Treatment During (...) Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) This study has been completed. Sponsor: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Merck Sharp & Dohme Corp. ClinicalTrials.gov Identifier: NCT01340768 First received: March 24, 2011 Last updated: February 4, 2016 Last verified (...) International journal of clinical practice Int. J. Clin. Pract. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. 626-31 10.1111/ijcp.12607 In the USA, 45% of patients with type 2 diabetes mellitus (T2DM) are elderly (≥ 65 years old). In general (...) , use of sulfonylurea increases with patient age as does the associated risk for hypoglycaemia, and the consequences of hypoglycaemia can be more pronounced in elderly patients. Sitagliptin

2018 Trip Latest and Greatest

70. Glipizide

of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular (...) complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36-80 years), were (...) enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily 2013 4. TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). OBJECTIVE: The rs7903146 T allele in transcription-factor-7-like-2 ( TCF7L2 ) is strongly associated with type 2 diabetes (T2D), but the mechanisms for increased risk remain unclear. We

2018 Trip Latest and Greatest

71. AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm

to the new Endocrine Practice website. Click to access your account and reset your password if this is your first visit. TheIP ranges for your institution have already been added to your account. You maywish to review this information under the Institutional administration tab inyour User Profile. Not Yet Registered? Benefits of Registration Include: A Unique User Profile that will allow you to manage your current subscriptions (including online access) The ability to create favorites lists down (...) Physician, Birmingham VAMC, Birmingham, Alabama 13 Chairman, Grunberger Diabetes Institute, Clinical Professor, Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Professor, Internal Medicine, Oakland University William Beaumont School of Medicine, Visiting Professor, Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic, Past President, American Association of Clinical Endocrinologists 14 Medical Director & Principal

Full Text available with Trip Pro

2019 American Association of Clinical Endocrinologists

72. Global Vascular Guidelines for patients with chronic limb-threatening ischemia

Surgery, University of California San Francisco, 400 Parnassus Ave, Ste A581, San Francisco, CA 94143-2202 , x Andrew W. Bradbury Affiliations Department of Vascular Surgery, University of Birmingham, Birmingham, United Kingdom , MD (Co-Editor) b , x Philippe Kolh Affiliations Department of Biomedical and Preclinical Sciences, University Hospital of Liège, Wallonia, Belgium , MD (Co-Editor) c , x John V. White Affiliations Department of Surgery, Advocate Lutheran General Hospital, Niles, Ill , MD (...) of Vascular Sciences, Bangalore, India 6, 10 (co-lead), 13 (lead) None John White (Steering Committee) Advocate Lutheran General Hospital, Niles, Ill 6, 9 (co-lead) None Victor Aboyans Department of Cardiology, Dupuytren University Hospital, France 1, 2 (co-lead), 7 Bayer (honoraria, Scientific Advisory Committee) Amgen Novartis (honoraria) Pfizer/BMS Alliance Sanofi Murat Aksoy Department of Vascular Surgery American Hospital, Turkey 1, 3, 5 None Vlad-Adrian Alexandrescu University of Liège CHU Sart

Full Text available with Trip Pro

2019 Society for Vascular Surgery

73. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

and obesity, counseling and caloric restriction are recommended for achieving and maintaining weight loss. 5. Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-intensity physical activity. 6. For adults with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed (...) by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit. 9. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low- density lipoprotein cholesterol

2019 American Heart Association

74. Diagnosis and Management of Glycogen Stored Diseases type VI and IX a practice resource of ACMG

pathogenic variants throughout the gene have been reported. If only one pathogenic variant is found in either the PHKG2 or PHKB gene, deletion/duplication testing is recommended becauselarge deletions and duplicationscan be missed by DNA sequencing. ACMG PRACTICE RESOURCE KISHNANI et al 8 Volume 0 | Number 0 | Month | GENETICS in MEDICINELaboratory diagnostic testing recommendations: ? To avoid liver biopsy, consider DNA testing first. Use of next-generation sequencing panels is recommended because (...) as an educational resource. It highlights current practices and therapeutic approaches to the diagnosis and management of the multiple complications of glycogen storage disease (GSD) types VI and IX. GENERAL BACKGROUND Overview Glycogen is the main storage form of carbohydrate in humans. It is most abundant in liver and muscle but is also present in other tissues. Glycogen is a polymer made up of highly branched chains of glucose molecules. In the liver, glycogen acts as a glucose reserve for maintenance

2019 American College of Medical Genetics and Genomics

75. Primary Prevention of Cardiovascular Disease

with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently (...) in the routine primary prevention of ASCVD because of lack of net benefit. 9. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low- density lipoprotein cholesterol levels (=190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and those determined to be at sufficient ASCVD risk after a clinician–patient risk discussion. 10. Nonpharmacological interventions are recommended for all adults with elevated blood pressure or hypertension. For those

2019 American College of Cardiology

76. Treatment of Diabetes in Older Adults

Press Permissions Icon Navbar Search Filter Mobile Microsite Search Term Close search filter search input Abstract Objective The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic (...) remark: This recommendation is most applicable to high-risk patients with any of the following characteristics: overweight or obese, first-degree relative with diabetes, high-risk race/ethnicity ( e.g. , African American, Latino, Native American, Asian American, Pacific Islander), history of cardiovascular disease, hypertension (≥140/90 mm Hg or on therapy for hypertension), high-density lipoprotein cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L), sleep

2019 The Endocrine Society

77. CRACKCast E206 – Seizures

activity and increased synchronicity allows you to both explain the initial presentation and progression of seizure activity. Seizures can be characterized as falling into one of the categories: Primary versus Secondary Primary seizures are by definition unprovoked and not linked to some inciting event Secondary seizures occur as the result of some underlying pathophysiologic process such as toxic ingestion, trauma, metabolic disturbances, structural lesions etc… Generalized versus Focal Generalized (...) seizures are typified by abnormal neuronal activity in BOTH hemispheres of the brain, resulting in a loss of consciousness or change in level of alertness Generalized seizures can be further categorized as being either: Tonic-clonic Absence-type Atonic Myoclonic Focal seizures occur in one hemisphere, thus allowing the patient to maintain consciousness It is important to note that these seizures can become secondarily generalized Convulsive versus Non-convulsive Convulsive seizures are typified

2019 CandiEM

78. Cardiovascular Outcome Trials for Type 2 Diabetes

of sitagliptin (100 mg or 50 mg in patients with eGFR 30mL/min to 50 mL/min) compared with placebo. Enrolled patients had T2DM with established CVD and were at least 50 years of age, with A1C of 6.5% to 9.0% when treated with stable doses of one or two oral antihyperglycemic agents (metformin, pioglitazone, or sulfonylurea) or insulin (with or without metformin). 25 The primary end point was a composite CV outcome defined as the first confirmed event of CV death, non-fatal MI, non-fatal stroke (...) with T2DM and established CVD Population: patients with T2DM with established CVD who were at least 50 years of age, with A1C of 6.5% to 9.0% when treated with stable doses of one or two oral antihyperglycemic agents (metformin, pioglitazone, or sulfonylurea) or insulin (with or without metformin) Intervention: daily doses of sitagliptin (100 mg or 50 mg in patients with eGFR 30 mL/min to 50 mL/min) Comparator: placebo Outcomes: Primary: composite CV outcome defined as the first confirmed event of CV

2019 CADTH - Issues in Emerging Health Technologies

79. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

2013 and 23 June 2016. The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Kristina Dunder Co-Rapporteur: Agnes Gyurasics • The application was received by the EMA on 1 February 2017. • The procedure started on 23 February 2017. • The Rapporteur's first Assessment Report was circulated to all CHMP members on 15 May 2017. The Co (...) -Rapporteur's first Assessment Report was circulated to all CHMP members on 22 May 2017. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 29 May 2017. • During the meeting on 22 June 2017, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. • The applicant submitted the responses to the CHMP consolidated List of Questions on 7 September 2017. • The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List

2018 European Medicines Agency - EPARs

80. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

analysis plan SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics SMQ Standard MedDRA Query SOC System organ class T2DM type 2 diabetes mellitus TAMC total aerobic microbial count Tmax time to first occurrence of maximum observed concentration TYMC total combined yeasts/moulds count UGE urinary glucose excretion ULN upper limit of normal US United States USPI United States Prescribing Information UTI urinary tract infection UV ultraviolet (...) The applicant received Scientific Advice from the CHMP on 22 September 2011, 19 December 2013 and on 21 May 2015. The Scientific Advice pertained to clinical aspects of the dossier. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Kristina Dunder Co-Rapporteur: Agnes Gyurasics • The application was received by the EMA on 27 January 2017. • The procedure started on 23 February 2017. • The Rapporteur's first Assessment Report

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>